New hope for advanced cancers: first human trial of DXC008 begins

NCT ID NCT06926283

Recruiting now Disease control Sponsor: Hangzhou DAC Biotechnology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This early-phase study tests a new drug called DXC008 in people with prostate cancer or other solid tumors (like Ewing sarcoma) who have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 110 adults aged 18 to 75 will take part in this first-in-human trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EWING SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ewing sarcoma neoplasm prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EWING SARCOMA OTHER SOLID TUMORS PROSTATE CANCER

Contacts and locations

Locations

Hunan Cancer Hospital
RECRUITING

Changsha, Hunan, 410000, China
Peking University First Hospital
RECRUITING

Beijing, 100034, China
Peking University People's Hospital
RECRUITING

Beijing, 100044, China
Zhejiang Provincial People's Hospital
RECRUITING

Hangzhou, Zhejiang, 310014, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.